The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A proprietary multi-analyte test to predict neoadjuvant treatment response for esophageal and rectal adenocarcinoma patients.
Sunil S. Badve
No relevant relationships to disclose
Weiwei Shan
Employment or Leadership Position - Castle Biosciences
Clare Johnson
Employment or Leadership Position - Castle Biosciences
Stock Ownership - Castle Biosciences
Yaeli Biermann-Harrar
No relevant relationships to disclose
Kristen M. Oelschlager
Employment or Leadership Position - Castle Biosciences
Stock Ownership - Castle Biosciences
Derek Maetzold
Employment or Leadership Position - Castle Biosciences
Stock Ownership - Castle Biosciences
Kenneth Kessler
No relevant relationships to disclose
Romil Saxena
No relevant relationships to disclose
Daniel Rosen
No relevant relationships to disclose
Robert W. Cook
Employment or Leadership Position - Castle Biosciences
Stock Ownership - Castle Biosciences